WO2008077062A3 - Suppression of stat3 reactivation after src kinase inhibition to treat cancer - Google Patents

Suppression of stat3 reactivation after src kinase inhibition to treat cancer Download PDF

Info

Publication number
WO2008077062A3
WO2008077062A3 PCT/US2007/087980 US2007087980W WO2008077062A3 WO 2008077062 A3 WO2008077062 A3 WO 2008077062A3 US 2007087980 W US2007087980 W US 2007087980W WO 2008077062 A3 WO2008077062 A3 WO 2008077062A3
Authority
WO
WIPO (PCT)
Prior art keywords
stat3
inhibitor
reactivation
sfk
suppression
Prior art date
Application number
PCT/US2007/087980
Other languages
French (fr)
Other versions
WO2008077062A2 (en
Inventor
Faye M Johnson
Nicholas J Donato
Original Assignee
Univ Texas
Faye M Johnson
Nicholas J Donato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Faye M Johnson, Nicholas J Donato filed Critical Univ Texas
Publication of WO2008077062A2 publication Critical patent/WO2008077062A2/en
Publication of WO2008077062A3 publication Critical patent/WO2008077062A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods of treating cancer are disclosed that comprise administering an inhibitor of SFK in a therapeutically effective amount to the subject wherein STAT3 is durably inhibited. The methods include the administration of an SFK inhibitor in combination with a suitable inhibitor of STAT3 reactivation including a STAT3 inhibitor, a JAK inhibitor or any molecule that inhibits STAT3 reactivation or the compensatory pathway for cell survial after inhibition of the SFK. Also provided are therapeutic compositions comprising an SFK inhibitor in combination with at least one inhibitor of STAT3 reactivation.
PCT/US2007/087980 2006-12-19 2007-12-18 Suppression of stat3 reactivation after src kinase inhibition to treat cancer WO2008077062A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87068206P 2006-12-19 2006-12-19
US60/870,682 2006-12-19

Publications (2)

Publication Number Publication Date
WO2008077062A2 WO2008077062A2 (en) 2008-06-26
WO2008077062A3 true WO2008077062A3 (en) 2008-10-09

Family

ID=39537057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/087980 WO2008077062A2 (en) 2006-12-19 2007-12-18 Suppression of stat3 reactivation after src kinase inhibition to treat cancer

Country Status (1)

Country Link
WO (1) WO2008077062A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3050566T3 (en) 2007-09-10 2019-03-11 Boston Biomedical Inc NEW GROUP OF STAT3 PATHWAY INHIBITORS AND CANCERCELLE-PATHWAY INHIBITORS
EP2370082A4 (en) * 2008-12-01 2012-05-30 Univ Central Florida Res Found Drug composition cytotoxic for pancreatic cancer cells
SA111320200B1 (en) 2010-02-17 2014-02-16 ديبيوفارم اس ايه Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
JP6433085B2 (en) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド 2-acetylnaphtho [2,3-b] furan-4,9-dione for use in the treatment of cancer
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN113082036B (en) * 2021-03-17 2022-11-01 中国海洋大学 Dual inhibitor targeting JAK/STAT and NF kappa B signal pathways and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAWAKAYA F.: "SFK-STAT pathway: an alternative and important way to malignancies", ANN. NY. ACAD. SCI., vol. 1086, 2006, pages 213 - 222 *

Also Published As

Publication number Publication date
WO2008077062A2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
WO2008077062A3 (en) Suppression of stat3 reactivation after src kinase inhibition to treat cancer
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
WO2004103274A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
MX2009010132A (en) Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors.
WO2003097052A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008116129A3 (en) Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
UA99141C2 (en) Substituted indazole derivatives active as kinase inhibitors
WO2008070795A3 (en) Combination therapy using low-dose doxepin for the improvement of sleep
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2008076949A3 (en) Quinazoline derivatives and methods of treatment
WO2009002808A3 (en) Quinazolinone compounds and methods of use thereof
WO2010124283A3 (en) Methods and compositions relating to hematologic malignancies
WO2008116053A3 (en) Fap-activated chemotherapeutic compounds, and methods of use thereof
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
WO2007095389A3 (en) Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
WO2012012305A3 (en) Combination therapy using a ruthenium complex
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
MX2011011687A (en) Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer.
MX338047B (en) Pharmaceutical combination.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07865824

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07865824

Country of ref document: EP

Kind code of ref document: A2